B+
Bull case
25%
Probability
Target price
$68.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
VERA
Vera TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
TRUTAKNA has accelerated FDA approval for adult IgA nephropathy and is positioned by Vera as the first and only approved BAFF/APRIL inhibitor in the indication. The company cites approximately 160,000 diagnosed U.S.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.7.
What can break
CEO open-market sales reported in July 2026 could weigh on investor sentiment, although they do not establish an operating or fundamental problem [#SEC-FORM4-2026-07-09].
Momentum
23
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $46.00 · Bull $68.00 · Bear $22.00Analysis 2026-09-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $77.64
Why
Momentum23 · Δ7d +1.5
Value41 · Δ7d -0.0
Sentiment100 · Δ7d +8.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.7.
Contradictions & invalidation
- • CEO open-market sales reported in July 2026 could weigh on investor sentiment, although they do not establish an operating or fundamental problem [#SEC-FORM4-2026-07-09].
- • Commercial-stage execution and cash-burn requirements may increase financing or dilution risk.
- • The approval is accelerated rather than full, leaving confirmatory ORIGIN 3 efficacy and longer-term eGFR evidence as important execution and regulatory risks.
Catalyst clock
2026-09-30
ORIGIN 3 final efficacy analysis
Lead driver: Sentiment · See AI snapshot
Momentum
23
9% active weight
Current posture
7d trendSoftening
Δ7d
+1.5
Δ21d
+11.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+8.7
Δ21d
0.0
Why this grade
Composite grade A. Momentum 22.8 / Value 41.2 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-04. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$46.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.28B
Beta
1.16
Shares Out
72.06M
P/E (TTM) · Derived
-6.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.42
Rev YoY
-
EPS YoY
+27.0%
Gross Margin
-
Op Margin
-
Net Debt
-$637.28M
Current Ratio
10.65
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data